Defining the next generation
of CAR T cell therapy
Verismo Therapeutics is pioneering CAR T cell therapy for the treatment of solid tumors and blood cancers. This paradigm-shifting technology features a novel, multi-chain KIR-CAR construct with a naturally inspired signaling mechanism design that acts as a natural on/off switch.
This new KIR-CAR platform has been proven to reduce T cell exhaustion and eliminate solid tumors in pre-clinical studies.
The paradigm shift in CAR T cell therapy
Verismo’s paradigm-shifting KIR-CAR platform with multi-chain immunoreceptor design may:
- Increase T cell persistence
- Overcome challenging solid tumor micro-environments
- Reduce off-target toxicities, leading to a more favorable safety profile
CAR T cell therapies with conventional single-chain construct:
- Fail to durably eliminate solid tumors and blood cancers
- Exhibit premature exhaustion of T cells through tonic signaling
- May lead to greater safety or toxicity concerns
Verismo’s KIR-CAR platform is currently under clinical evaluation for solid tumors and blood cancers
Verismo is pioneering the further development of novel chimeric antigen receptors (CARs) by leveraging the signaling pathway of killer immunoglobulin-like receptors (KIRs) naturally existing in NK cells, creating their KIR-CAR platform and flagship therapies; SynKIR™-110 and SynKIR™-310.
With its naturally inspired signaling mechanism designed to turn on and off as needed, KIR-CAR has shown the potential to overcome T cell exhaustion and off-target toxicity common in conventional CAR T treatments.
The experts behind KIR-CAR and SynKIR™
Verismo was founded by the inventors of Kymriah™. This team saw an opportunity to overcome the limitations found in conventional CAR T cell therapies, through the use of a KIR-CAR platform.
